Skip to content

Transfer of feces in ulcerative colitis 2; improving efficacy

Transfer of feces in ulcerative colitis 2; improving efficacy - TURN 2 trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52507
Enrollment
76
Registered
2018-05-25
Start date
2018-12-05
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease Ulcerative colitis

Interventions

One group will be treated with faecal transplantation from a healthy donor, the other group will be treated with autologous faeces as a placebo.

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age >=18 and = 2 in either the rectum or sigmoid upon screening sigmoidoscopy • Stable dose of thiopurines, 5-ASA, in preceding 8 weeks, stable budesonide use in preciding 2 weeks, prednisone use 1.5x ULN in the subgroup of PSC/UC patients

Exclusion criteria

Exclusion criteria: • Condition leading to profound immunosuppression o For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies o Use of systemic chemotherapy o Child-Pugh B liver cirrhosis • Anti-TNF treatment in preceding 2 months Vedolizumab, tofacitinib and/or ustekinumab treatment in preceding 2 months • Cyclosporine treatment in preceding 4 weeks • Use of Methotrexate in preceding 2 months • Prednisolone dose > 15 mg/day in preceding 2 weeks • Use of topical therapy in preceding 2 weeks • Life expectancy

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the proportion of study subjects in clinical and endoscopic remission per adapted Mayo: stool frequency subscores (SFS)

Secondary

MeasureTime frame
- Proportion of patients with a clinical response per Adapted Mayo at week 8: decrease from baseline >= 2 points and >= 30% plus a decrease in RBS >= 1 or an absolute RBS =1 point reduction in summed endoscopic Mayo score of both the rectum and sigmoid at week 8. - Proportion of patients in sustained steroid-free remission per adapated mayo at week 12: stool frequence subscore (SFS) 1 points and >30% plus a decrease in RBS >1 or an absolute RBS 1 - Proportion of patients with: o Endoscopic improvement: Endoscopic subscore of 0 or 1 at week 8 o Endoscopic remission: endoscopic subscore = 0 at week 8 o Histological Remission: Geboes score of

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 19, 2026